UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934

AstraZeneca PLC

(Exact name of registrant as specified in its charter)

AstraZeneca Finance LLC

(Exact name of registrant as specified in its charter)

Securities to be registered pursuant to Section 12(b) of the Act:

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. x

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ¨

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ¨

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-278067

Securities to be registered pursuant to Section 12(g) of the Act: None.

INFORMATION REQUIRED IN REGISTRATION STATEMENT

AstraZeneca PLC ("AstraZeneca") and AstraZeneca Finance LLC ("AstraZeneca Finance" and, together with AstraZeneca, the "Registrants") filed with the Securities and Exchange Commission (the "Commission") pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the "Securities Act"), a prospectus supplement, dated February 25, 2026 (the "Prospectus Supplement"), and the accompanying prospectus, dated March 19, 2024 (the "Prospectus"). The Prospectus Supplement relates to the offering of $650,000,000 4.000% Notes due 2031, $600,000,000 4.300% Notes due 2033 and $750,000,000 4.600% Notes due 2036 issued by AstraZeneca Finance and fully and unconditionally guaranteed by AstraZeneca. The Prospectus forms a part of the Registrants' Registration Statement on Form F-3 (File No. 333-278067) filed with the Commission on March 19, 2024. The Prospectus Supplement and the Prospectus are incorporated herein by reference to the extent set forth below.

Item 1. Description of Registrant's Securities to Be Registered.

Reference is made to the information set forth under the headings "Description of Debt Securities and Guarantees" on pages 15 through 31 and "Certain UK and U.S. Federal Tax Considerations" on pages 36 through 44 of the Prospectus; and to the information set forth under the headings "Description of Notes" on pages S-13 through S-18 and "Taxation" on page S-19 of the Prospectus Supplement, which information is incorporated herein by reference.

Item 2. Exhibits.

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, each Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

Dated: March 3, 2026